Table 2. Overall survival and disease-free survival in 123 patients with adenocarcinoma.
No. | 5-year survival | Log-rank | RFS at 36 (months)a | Log-rank | |
---|---|---|---|---|---|
(%) | (%) | P-value | (%) | P-value | |
Age | |||||
≦48 | 67 (54) | 84 | 0.091 | 85 | 0.017 |
>48 | 56 (46) | 77 | 80 | ||
FIGO stage | |||||
IB | 96 (78) | 86 | 0.004 | 89 | 0.001 |
IIA | 5 (4) | 53 | 60 | ||
IIB | 22 (18) | 59 | 59 | ||
Tumour size (mm) | |||||
≦20 | 37 (30) | 95 | <0.001 | 97 | <0.001 |
21–40 | 46 (37) | 91 | 91 | ||
>40 | 40 (33) | 55 | 59 | ||
Depth in cervical wall | |||||
<1/3 | 34 (28) | 97 | 0.004 | 100 | 0.001 |
1/3–2/3 | 31 (25) | 87 | 87 | ||
>2/3 | 58 (47) | 67 | 87 | ||
Number of positive nodes | |||||
None | 91 (74) | 91 | <0.001 | 93 | <0.001 |
1–4 | 25 (20) | 60 | 63 | ||
≧5 | 7 (6) | 14 | 14 | ||
LVS invasion b | |||||
None | 53 (43) | 98 | <0.001 | 98 | <0.001 |
Few | 32 (26) | 81 | 84 | ||
Several | 27 (22) | 56 | 61 | ||
Many | 11 (9) | 55 | 55 | ||
Parametrial invasion | |||||
Negative | 102 (83) | 89 | <0.001 | 92 | <0.001 |
Positive | 21 (17) | 38 | 43 | ||
Infiltration to vagina | |||||
No | 94 (76) | 87 | <0.001 | 89 | <0.001 |
Yes | 29 (24) | 61 | 62 | ||
Ovarian metastases | |||||
Negative | 94 (95) | 84 | <0.001 | 85 | <0.001 |
Positive | 6 (5) | 17 | 20 | ||
Histological subtype | |||||
Mucinous | 73 (59) | 75 | 0.543 | 78 | 0.180 |
Endometrioid | 50 (41) | 88 | 90 | ||
Histological grade | |||||
Grade 1 | 86 (70) | 85 | <0.001 | 86 | <0.001 |
Grade 2 | 23 (19) | 87 | 86 | ||
Grade 3 | 14 (11) | 47 | 56 |
FIGO=the International Federation of Gynecology and Obstetrics; LVS=lymph–vascular space; RFS=relapse-free survival.
RFS at 36 months.
LVS invasion.